A larger sample size, a longer follow-up, unified characteristics of participants (such as diabetes duration and C-peptide levels), the comprehensive monitoring of glycemia and relevant hormone levels, the use of immunological indicators (such as CD4+ and CD8+ T cells), and a report of full-scale adverse effects should be the focus of future studies. Here, CD8A is linked to diabetes mellitus.